PCAC review · February 2027 panel
FDA's Pharmacy Compounding Advisory Committee scheduled to review the second cohort of peptides removed from Category 2 in April 2026. Panel votes whether to add each to the official 503A bulks list.
PEG-MGF
Monograph · DPegylated Mechano Growth Factor — synthetic Ec splice variant of IGF-1 with PEGylation for extended half-life. Local muscle stem-cell activation and tissue repair signaling.
How it clearsHalf cleared in ~2d. Most (~96%) gone by ~10d.
Compare these compounds
Mechanism, evidence, legal path, cost — all side-by-side.

Evidence is experimental. Most claims trace to limited human studies or animal models. Treat as a research direction, not a protocol.
MGF (IGF-1Ec) is the splice variant produced locally in muscle in response to mechanical stress. PEGylation extends the otherwise minutes-long half-life. Preclinical models show satellite cell proliferation and accelerated regeneration after injury. No human clinical trials. Often paired with IGF-1 LR3 in physique-community stacks; often counterfeit in grey market.
Thin data — the mechanism is biologically plausible, but human response evidence is mostly case reports and personal logs. If you're running this, careful tracking is not optional — it is the evidence base this tier is still building.
No human safety data. Local IGF-1 axis activation creates unknown long-term tissue-overgrowth and cancer-promotion concerns. Identity verification of grey-market product is poor — PEG-MGF is among the most counterfeited peptides.
Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.
Upload in /historyPer-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Expected reclassification — PCAC review Feb 2027
FDA's Pharmacy Compounding Advisory Committee scheduled to review the second cohort of peptides removed from Category 2 in April 2026. Panel votes whether to add each to the official 503A bulks list.
Pre-filled with this compound's published dose range: 100-200 µg · post-workout, intramuscular at target site
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
How much a first cycle actually costs across the channels people use. Pick the protocol length you're considering — Stack multiplies the monthly band by cycle weeks. Same caveats apply: ranges are facts, quality varies, this is not legal advice.
Numbers reflect publicly-advertised price ranges, not vendor quotes. Insurance, prescription costs, and shipping aren't included. Channels marked unavailable are filtered out.
See pharmacies for this compound →Approximate monthly cost across the channels users actually consider — brand FDA-approved retail, US 503A compounding, Mexican pharmacies, MX farmacias magistrales, and the research-grey market. Stack lists ranges, not vendor names. Quality varies wildly across channels — see each band's note.
Dosing assumption: 200-500 µg post-workout subcutaneous (mechano growth factor, PEGylated)
Research-grey only. PEGylation extends half-life vs. regular MGF — most community use targets local hypertrophy. WADA-banned for sport. On the Feb 2027 PCAC docket.
As of 2026-04No field reports yet
Field reports are added as users share their real-world protocols.
Next visit & citations
Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.